Advanced soft tissue laser system now cleared for use across Canada.
BOSTON, MA | July 7, 2025 – InnoVoyce, a medical technology company dedicated to advancing surgical laser innovation, today announced that its VYLO™ 455nm Blue Light Laser System has been approved by Health Canada. Issued under License No. 113519, the Class III device is now authorized for clinical use in a broad range of soft tissue procedures across Canada.
The VYLO Laser System delivers up to 30 watts of power and features four emission modes: pulsed, continuous, quasi pulsed, and quasi continuous, providing physicians with the versatility to match laser performance to a wide spectrum of surgical needs. The VYLO system is approved for the incision, excision, vaporization, ablation, hemostasis, and coagulation of soft tissue, including mucosal membranes, skin, glands, and vascular structures.
“Health Canada approval marks an important milestone in our mission to bring high precision laser technology to more physicians and patients,” said Michael Davin, CEO of InnoVoyce. “VYLO was engineered with the surgical experience in mind. From its emission modes to its wavelength specificity, every feature is designed to give physicians more versatility, more precision, and better outcomes for their patients.”
The 455nm wavelength of the VYLO laser is highly absorbed by hemoglobin, allowing for focused energy delivery in vascular procedures and tissue-selective applications. Clinical use to date has demonstrated strong utility in otolaryngology and laryngology, where VYLO’s performance has supported improved outcomes and workflow efficiency in both office-based and surgical environments.
One of VYLO’s most impactful features is its Quasi modes, which give surgeons the ability to adjust pulse duration and duty cycle during a procedure. This capability allows for more refined control of laser-tissue interaction, making it possible to tailor energy delivery based on the surgical objective. By modulating how long and how often energy is applied, Quasi modes support reduced thermal spread, improved coagulation, and greater precision when working in delicate anatomical areas. This adaptability enhances surgical versatility across a variety of clinical scenarios.
The VYLO system is indicated for use in general surgery, gastroenterology, gynecology, otolaryngology, neurosurgery, ophthalmology, plastic surgery, spinal surgery, thoracic surgery, and urology. Its compact footprint and ergonomic mobility make it well suited for both the clinical settings and operating rooms. With Health Canada approval now in place, InnoVoyce continues its expansion into international markets, making advanced blue light laser technology more widely accessible for modern surgical care.
For more information on the VYLO Laser System, visit www.innovoyce.com
About InnoVoyce
InnoVoyce is at the forefront of innovation, developing cutting-edge, solid-state laser technologies for clinical and surgical settings. As a leading provider, we exceed expectations through our clinically validated, high-quality solutions and unparalleled customer service. Driven by a mission to empower healthcare professionals, InnoVoyce is committed to delivering advanced technology supported by robust scientific evidence and endorsements from renowned institutions and surgeons. Our collaboration with top-tier medical and scientific experts ensures our products align with technological excellence, making a positive impact on laser science worldwide.
Media contact:
Sheree Titan-Ford, InnoVoyce. 508-308-7019 or Sheree.Titan.Ford@InnoVoyce.com
